Mindblown: a blog about philosophy.

Findings Suggest Blood Collection Device Simplifies Specimen Collection and Transport While Maintaining Accuracy of Diagnostic Test Results Boulder, CO, December 15, 2020 – Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced publication of a peer-reviewed study supporting its patented blood collection device (BCD). The device is designed to streamline whole blood…

Generates record quarterly revenue of $9.2 million Raises net proceeds of $63 million through initial public offering Adds to the significant and growing body of evidence demonstrating the clinical value of its portfolio of blood based diagnostic tests for lung disease Boulder, CO, December 10, 2020 –Biodesix, Inc. a leading data-driven diagnostic solutions company with a…

Assessment Confirms Test Performance After Two Years of Surveillance BOULDER, CO, October 28, 2020 – Biodesix, Inc. (Nasdaq: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced publication of an analysis of the company’s Nodify XL2® lung nodule test. The test supports clinical decision-making for suspicious nodules by more accurately…

BOULDER, CO, October 28, 2020 – Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix”) today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $18.00 per share. The shares are expected to begin trading on The Nasdaq Global Market on October 28, 2020, under the symbol “BDSX.” The offering is…

Research Evaluates Risk Classification for Patients with Lung Nodules Boulder, CO, October 20, 2020 – Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, recently published data from three clinical studies, which found important new information on diagnosis and management of lung nodules. Data from these studies, which are being…

Biodesix, Inc. to oversee onsite surveillance testing of Quidel Corporation’s rapidSOFIA 2 SARS Antigen FIA test All involved in close contact Big Ten Conference sport competition to receive Quidel rapid antigensurveillance testing with additional validity testing through the Biodesix Laboratory ROSEMONT, Ill. – The Big Ten Conference has entered into strategic partnerships with Biodesix, Inc.,…

Dr. Mary Jo Fidler of Rush University Medical Center Named Principal Investigator San Carlos, CA and Boulder, CO, August 31, 2019 – Addario Lung Cancer Medical Institute (ALCMI) and Biodesix, Inc. today announced they will begin an observational study to prospectively evaluate the clinical utility of biomarkers, including the proteomic Primary Immune Response (PIR) test,…

Biodesix Prepares to Test Thousands as Students Return to Campus BOULDER, CO, August 12, 2020 – Biodesix, Inc., a leading diagnostic company with a focus in lung disease, today announced plans to provide COVID-19 ddPCR diagnostic testing for Colorado State University (CSU) as students return to campus for the fall term, which begins August 24.…

BOULDER, CO, July 16, 2020 – Biodesix, Inc., a leader in lung cancer diagnostics, today announced the appointment of Jean Franchi and Hany Massarany to the company’s board of directors. Ms. Franchi has more than 30 years of biotechnology and life science industry experience ranging from pre-commercial to global commercial biotech operations. Mr. Massarany has…